Pancreatic cancer cells are glutamine dependent for growth and proliferation. The glutamine transporter SLC1A5 is upregulated in pancreatic cancer and is being actively investigated as a pharmacological target. We genetically engineered human pancreatic cancer cells to express SLC1A5 shRNA to downregulate SLC1A5. 1H MRS was used to analyze metabolic differences in SLC1A5 downregulated Pa04C_SLC1A5 pancreatic cancer cells and tumors compared to empty vector cells and tumors. SLC1A5 downregulation resulted in a significantly lower glutamine/glutamate ratio in Pa04C_SLC1A5 cells. In Pa04C_SLC1A5 tumors we observed a significant reduction of several metabolites highlighting the metabolic reprogramming that occurred in tumors with SLC1A5 downregulation.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords